SpringWorks' Q4 Loss Wider Than Expected, Revenues Beat Estimates
SWTX reports mixed fourth-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.
Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Springworks Therapeutics (SWTX – Research ...
3SWTX : What the Options Market Tells Us About SpringWorks Therapeutics
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $40.0 and $60.0 for SpringWorks Therapeutics, spanning the last ...
SpringWorks Therapeutics price target lowered to $77 from $78 at Guggenheim
Guggenheim lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $77 from $78 and keeps a Buy rating on the shares. The firm is ...
Weekly Roundup: 15 Health Press Releases You Need to See
With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...
MM&M23h
SpringWorks teams with jewelry designer Jennifer Fisher for desmoid tumors push
Just over two years after establishing desmoidtumors.com, the drugmaker is teaming with Jennifer Fisher to empower patients.